CA-NOODLE.AI
16.1.2020 15:02:14 CET | Business Wire | Press release
Leading Enterprise Artificial Intelligence® provider Noodle.ai and the digitalization team at SMS group , a trailblazer in digitalization for plant and equipment used in steel and nonferrous-metals production and processing, launched MPV today. MPV is the first joint AI-driven application for the steel industry. The launch follows the announcement of their partnership in June 2019.
As steel industry margins continue to shrink, one promising way for manufacturers to increase profitability is to pursue more advanced, high-strength steel production for applications such as automotive and electrical. However, production of these advanced steel grades requires much tighter control of the overall production process, which is impacted by numerous parameters across the mill.
The MPV (Mechanical Properties Variability) application utilizes artificial intelligence and machine learning to create a unique 'sense, predict, and recommend' framework that addresses challenges associated with the variability of mechanical properties in steel production. Mechanical properties include things such as yield strength, tensile strength, and elongation. The application senses patterns within mill data to fully understand the drivers of mechanical property variability. It then predicts when increased variability will occur and recommends the optimal input parameters, or PDI settings, required to optimize target mechanical properties such as yield strength, tensile strength, and elongation. As a result, the MPV application can help steel manufacturers achieve cost savings 3 ways: by reducing mechanical properties variability, reducing alloy costs due to better variability control, and minimizing out-of-spec production, which are sold as secondary grades or scrapped. One steel manufacturer using MPV is anticipating savings $2M per year.
“Our ability to deploy AI to produce steel with tighter tolerances allows us to address the requirements of high margin segments such as automotive and electrical, which immediately impacts our top line revenues in addition to the obvious cost savings,” said Denis Hennessy, Director of Product Development at Big River Steel, after implementing the MPV application.
In addition to addressing these challenges in mechanical properties variability, the AI and machine learning solutions that Noodle.ai and SMS digital have co-developed will also help steel manufacturers optimize product quality, asset availability and production efficiency. Together, Noodle.ai and SMS digital combine manufacturing equipment expertise, process modeling experience, and cutting-edge data science to accelerate time to value, enabling customers to quickly realize bottom-line impact.
“This partnership with SMS digital was created to make efficiency improvements that not only help steel manufacturers’ bottom line, but to rid the world of unnecessary industrial waste that often plagues this industry,” said Stephen Pratt, Founder and CEO, Noodle.ai. “We are encouraged by the results we’ve already seen with this application developed in partnership with SMS digital, and anticipate being able to assist an even larger list of steel manufacturers as we enter 2020 with MPV and the other applications we develop together.”
About Noodle.ai
Noodle.ai applies advanced data science to industries at the core of the global economy to create a world without waste. With Noodle.ai’s advanced Enterprise AI® applications, business leaders are empowered to make better decisions, reduce wasted energy, money, and resources, and ensure their businesses are built to last. Noodle.ai focuses on radical efficiency for supply chain and manufacturing using leading-edge artificial intelligence.
About SMS digital comprising SMS group Inc. Digital Solutions and SMS digital GmbH
SMS digital GmbH, the digital subsidiary of SMS group GmbH, and SMS group Inc. Digital Solutions collectively are a market leading supplier of digitalization for plant and equipment used in steel and NF-metals production and processing. SMS group GmbH generates worldwide sales totaling EUR 3.3 billion with more than 14,000 employees.
In close collaboration with its customers, SMS digital identifies and develops innovative products for the metals industry building on most advanced development techniques, in-depth metallurgical process knowhow and technological expert knowledge. SMS digital helps its customers make their plants and machines ready for the digital age by means of digital applications and the use of AI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom